Latest Articles

Publication Date
Comparative study of quality of life between endometriosis patients receiving GnRH agonist and dienogest therapy: A cross-sectional study using Endometriosis Health Profile-30 (EHP-30).

Endometriosis is a chronic gynecological disease that substantially impairs quality of life. Gonadotropin-releasing hormone (GnRH) agonists and dienogest are commonly used hormonal therapies for endometriosis; however, direct comparisons of their …

Published: June 25, 2026, midnight
Revisiting endometriosis management: Polyphenols as alternative therapeutic candidates.

Endometriosis (EM) is a common gynecological disorder imposing a considerable burden on the quality of life of women through chronic pain, infertility, and other clinical manifestations. The effectiveness of management …

Published: June 24, 2026, midnight
Role of hormonal therapies in endometriosis: balancing efficacy and safety.

Endometriosis is a chronic, estrogen-dependent inflammatory disorder requiring long-term management strategies that balance efficacy with systemic safety. Although hormonal therapies remain the cornerstone of treatment, the optimal degree of estrogen …

Published: June 10, 2026, midnight
Endometriosis and ovarian cancer: epidemiological evidence, molecular insights, and clinical decision-making.

Endometriosis, particularly ovarian endometrioma, is associated with a 2-fold increased risk of ovarian cancer (OC), especially the clear cell and endometrioid subtypes. However, the absolute lifetime risk of OC in …

Published: May 17, 2026, midnight
Endometriosis in Adolescents: A Literature Review.

Endometriosis is a chronic gynecological disorder that affects approximately 10% of women of reproductive age. In adolescents, it frequently remains underdiagnosed due to the heterogeneity of its clinical presentation. Pelvic …

Published: April 30, 2026, midnight
Synergistic effects of melatonin and dienogest on pain relief in endometriosis: a randomized controlled trial.

Endometriosis affects 5-10% of reproductive-aged women and is characterized by chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility. Standard hormonal therapies, such as dienogest, effectively manage symptoms, but are often associated …

Published: March 31, 2026, midnight
Lactoferrin as a Non-Hormonal Therapeutic Candidate for Endometriosis: Mechanisms and Future Directions.

The pathogenesis and progression of endometriosis may involve a complex combination of multiple factors, including chronic inflammation and oxidative stress. Hormonal therapy, the current standard for pharmacotherapy in endometriosis, causes …

Published: March 5, 2026, midnight
A Dive into the Invisible: The Vaginal and Endometrial Microbiota in Gynecologic and Obstetric Disorders: A Narrative Review.

The human microbiota is increasingly recognized as a key component of women's reproductive health. This narrative review examines the vaginal, endometrial, and gut microbiota and their roles in the pathogenesis …

Published: Feb. 17, 2026, midnight
2-Deoxyglucose dendrimer-enabled niclosamide delivery to FRβ-expressing macrophages alleviates endometriosis progression and associated hyperalgesia.

Endometriosis is a chronic, incurable disease. Due to limited efficacy, high recurrence rates, and serious side effects of current treatments, development of new, targeted, non-hormonal therapies is urgently needed. We …

Published: Feb. 12, 2026, midnight
Impact of hormonal treatments for endometriosis on the reproductive microbiome: a systematic review.

The reproductive microbiome plays a key role in disease progression and fertility in women with endometriosis. Vaginal and endometrial dysbiosis has been increasingly linked to inflammation, impaired reproductive outcomes, and …

Published: Feb. 12, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!